In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...
Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Russian Academy of Sciences, FSBIS Institute of Physiologically Active Compounds of the Russian Academy of Sciences, 1, Severny Proezd, Chernogolovka 142432, Russian Federation Russian Academy of ...
Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...
If you rotate an image of a molecular structure, a human can tell the rotated image is still the same molecule, but a machine-learning model might think it is a new data point. In computer science ...
Abstract: A general problem in multi-node systems is data synchronization, where the most used method uses synchronous data updating. All changes made by the user are immediately reflected in the data ...
Abstract: The fast and efficient in situ inspection of aircraft engine blades is crucial for maintaining the safety and reliability of aircraft engines. The automation and intelligence of aeroengine ...
Google DeepMind today pulled the curtain back on AlphaEvolve, an artificial-intelligence agent that can invent brand-new computer algorithms — then put them straight to work inside the company's vast ...
People store large quantities of data in their electronic devices and transfer some of this data to others, whether for professional or personal reasons. Data compression methods are thus of the ...
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results